Online inquiry

IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10430MR)

This product GTTS-WQ10430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Cachexia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10430MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8492MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ8805MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ11205MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ3178MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ4029MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ8388MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ950MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ9156MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW